S&P 500
5,844.61
-1.6%
-95.85
DJI
41,860.44
-1.9%
-816.80
NASDAQ
$18,872.64
-1.4%
-$270.07
Bitcoin
109,669.00
+2.8%
+2,938.68
AAPL
$202.42
-2.1%
-$4.44
AMZN
$201.35
-1.3%
-$2.72
GOOG
$170.25
+3.0%
+$4.93
META
$635.69
-0.2%
-$1.41
MSFT
$453.22
-1.1%
-$4.95
NVDA
$131.94
-1.8%
-$2.44
TSLA
$334.80
-2.6%
-$9.02
89bio (NASDAQ: ETNB)
$9.62
(6.5%)
$0.58
Price as of May 21, 2025, 3:58 p.m. ET
89bio Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
89bio Company Info
89bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases. Its product pipeline includes pegozafermin, FGF21, NASH, and SHTG. The company was founded on January 18, 2018 and is headquartered in San Francisco, CA.
News & Analysis
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.